HER2-SADA / SERB Pharmaceuticals, Memorial Sloan-Kettering Cancer Center, Massachusetts Institute of Technology - LARVOL DELTA

Pretargeted Radioimmunotherapy for HER2-Positive Gastric, Colorectal, and Ovarian Cancers: A Novel Approach to Enhance Targeted Radiotherapy (ACS-CLINCON 2025) - "HER2-SADA PRIT demonstrated high tumor selectivity, effective tumor regression, and prolonged survival without radiotoxicity in HER2-positive solid tumors. Its favorable biodistribution and minimal toxicity highlight a strong potential for clinical translation, offering a novel, promising HER2-targeted radiotherapeutic."

Colorectal Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2

HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS (CTOS 2024) - "Preclinical experiments show that the HER2 SADA antibody platform is a safe and effective method for delivery of alpha radiation to DSRCT. This treatment modality is capable of eliminating large (>1000 mm3) xenograft tumors without treatment-associated myelotoxicity. We propose that HER2-directed SADA PRIT is a promising strategy for DSRCT and should be further investigated."

Oncology • Soft Tissue Sarcoma • HER-2